Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure

Russell E.N. Becker, Max R. Kates, Trinity J. Bivalacqua

Research output: Contribution to journalReview article

Abstract

Disease progression and recurrence are common among patients on Bacillus Calmette-Guérin (BCG) therapy, and options for bladder-preserving subsequent therapy remain limited. Ongoing efforts to develop better second-line bladder-sparing therapies rely on clinical trials of patients deemed to have failed management with BCG. This article describes historical definitions of BCG failure, as well as recent efforts to better delineate and refine the clinical criteria for identifying individual patients who will not benefit from further intravesical BCG therapy. It also reviews guidance from the most recent expert consensus panels and professional association guidelines regarding which patients should not receive additional BCG therapy.

Original languageEnglish (US)
Pages (from-to)15-21
Number of pages7
JournalUrologic Clinics of North America
Volume47
Issue number1
DOIs
StatePublished - Feb 2020

Fingerprint

Salvage Therapy
Bacillus
Urinary Bladder
Therapeutics
Disease Progression
Clinical Trials
Guidelines
Recurrence

Keywords

  • Bacillus Calmette-Guérin failure
  • Bacillus Calmette-Guérin unresponsive
  • Bladder cancer
  • Intravesical therapy
  • Nonmuscle-invasive bladder cancer

ASJC Scopus subject areas

  • Urology

Cite this

Identification of Candidates for Salvage Therapy : The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure. / Becker, Russell E.N.; Kates, Max R.; Bivalacqua, Trinity J.

In: Urologic Clinics of North America, Vol. 47, No. 1, 02.2020, p. 15-21.

Research output: Contribution to journalReview article

@article{68b5d89ed74c4779b2ae8697f667de47,
title = "Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Gu{\'e}rin Failure",
abstract = "Disease progression and recurrence are common among patients on Bacillus Calmette-Gu{\'e}rin (BCG) therapy, and options for bladder-preserving subsequent therapy remain limited. Ongoing efforts to develop better second-line bladder-sparing therapies rely on clinical trials of patients deemed to have failed management with BCG. This article describes historical definitions of BCG failure, as well as recent efforts to better delineate and refine the clinical criteria for identifying individual patients who will not benefit from further intravesical BCG therapy. It also reviews guidance from the most recent expert consensus panels and professional association guidelines regarding which patients should not receive additional BCG therapy.",
keywords = "Bacillus Calmette-Gu{\'e}rin failure, Bacillus Calmette-Gu{\'e}rin unresponsive, Bladder cancer, Intravesical therapy, Nonmuscle-invasive bladder cancer",
author = "Becker, {Russell E.N.} and Kates, {Max R.} and Bivalacqua, {Trinity J.}",
year = "2020",
month = "2",
doi = "10.1016/j.ucl.2019.09.004",
language = "English (US)",
volume = "47",
pages = "15--21",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Identification of Candidates for Salvage Therapy

T2 - The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure

AU - Becker, Russell E.N.

AU - Kates, Max R.

AU - Bivalacqua, Trinity J.

PY - 2020/2

Y1 - 2020/2

N2 - Disease progression and recurrence are common among patients on Bacillus Calmette-Guérin (BCG) therapy, and options for bladder-preserving subsequent therapy remain limited. Ongoing efforts to develop better second-line bladder-sparing therapies rely on clinical trials of patients deemed to have failed management with BCG. This article describes historical definitions of BCG failure, as well as recent efforts to better delineate and refine the clinical criteria for identifying individual patients who will not benefit from further intravesical BCG therapy. It also reviews guidance from the most recent expert consensus panels and professional association guidelines regarding which patients should not receive additional BCG therapy.

AB - Disease progression and recurrence are common among patients on Bacillus Calmette-Guérin (BCG) therapy, and options for bladder-preserving subsequent therapy remain limited. Ongoing efforts to develop better second-line bladder-sparing therapies rely on clinical trials of patients deemed to have failed management with BCG. This article describes historical definitions of BCG failure, as well as recent efforts to better delineate and refine the clinical criteria for identifying individual patients who will not benefit from further intravesical BCG therapy. It also reviews guidance from the most recent expert consensus panels and professional association guidelines regarding which patients should not receive additional BCG therapy.

KW - Bacillus Calmette-Guérin failure

KW - Bacillus Calmette-Guérin unresponsive

KW - Bladder cancer

KW - Intravesical therapy

KW - Nonmuscle-invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=85075143150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075143150&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2019.09.004

DO - 10.1016/j.ucl.2019.09.004

M3 - Review article

C2 - 31757296

AN - SCOPUS:85075143150

VL - 47

SP - 15

EP - 21

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -